Comparative Pharmacology
Head-to-head clinical analysis: OXYTOCIN versus SYNTOCINON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYTOCIN versus SYNTOCINON.
OXYTOCIN vs SYNTOCINON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxytocin is a nonapeptide hormone that binds to oxytocin receptors on the myometrium, stimulating G-protein coupled receptor activation and increasing intracellular calcium, leading to uterine smooth muscle contraction. It also acts on mammary gland myoepithelial cells to induce milk ejection.
Synthetic oxytocin binds to oxytocin receptors in the myometrium, causing increased intracellular calcium and uterine smooth muscle contraction. Also acts on mammary gland myoepithelium for milk ejection.
For induction/augmentation of labor: IV infusion, initial 0.5-2 mU/min, increase by 1-2 mU/min every 30-60 min until desired contraction pattern; max 20 mU/min. For postpartum hemorrhage: IV bolus 3 units (slow push) or IV infusion 10-40 units in 1000 mL crystalloid, rate adjusted to control bleeding; alternatively IM 10 units after delivery of placenta.
10 units (1 mL) intravenously as a single dose after delivery; continuous infusion: 20 units in 1 L of normal saline or lactated Ringer's solution at 2-10 mU/min (0.1-0.5 mL/min) titrated to uterine response.
None Documented
None Documented
Terminal elimination half-life: 1–6 minutes (intravenous); clinical context: rapid offset requires continuous infusion for sustained uterine contraction.
Terminal elimination half-life: 1–6 minutes (intravenous); 1–9 minutes (intramuscular). Clinically, effects dissipate rapidly after infusion cessation.
Renal: >99% as intact oxytocin and metabolites; biliary/fecal: negligible.
Renal: >99% as intact oxytocin; biliary/fecal: negligible (<1%).
Category C
Category C
Oxytocic
Oxytocic